Clinical Trial Update: A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study of sacituzumab in combination with chemoimmunotherapy for advanced triple-negative breast cancer has been terminated, with results posted in J…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Advanced Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-06-12